Chip stocks fall with Nvidia after data center rev disappointment
In recent transactions involving biote Corp. (NASDAQ:BTMD), a company currently trading at $3.34 with a market capitalization of $129 million, Guines LLC acquired a significant number of Class A common shares over two consecutive days. According to InvestingPro analysis, the company maintains a "GREAT" Financial Health Score and appears slightly undervalued based on Fair Value estimates. On April 8, 2025, Guines LLC purchased 34,907 shares at a weighted average price of $3.2081 per share. The following day, April 9, they acquired an additional 13,532 shares at a weighted average price of $3.2074 per share. These acquisitions, totaling $155,387, were executed within price ranges of $3.15 to $3.25 and $3.18 to $3.25, respectively. This insider buying activity comes as the stock has fallen significantly over the past three months, with InvestingPro data showing multiple additional insights available for subscribers.
The transactions increased Guines LLC's holdings to 4,156,426 shares. These shares are directly owned by Guines LLC but may be indirectly beneficially owned by Roystone Management Holdings LLC, RB Management GP LLC, and Richard Barrera, as noted in the filing. The parties involved have clarified that they disclaim beneficial ownership except to the extent of their pecuniary interest. Discover comprehensive insights about BTMD and 1,400+ other stocks through detailed Pro Research Reports available on InvestingPro.
In other recent news, BioTE Corp reported its fourth-quarter 2024 earnings, which showed a slight miss on earnings per share (EPS) and revenue forecasts. The company posted an EPS of $0.10, falling short of the projected $0.11, and revenue of $49.8 million, which was below the expected $51.29 million. Jefferies and Truist Securities both adjusted their price targets for BioTE, lowering them to $6.80 and $7.00, respectively, but maintained a Buy rating on the stock. Analysts from both firms cited the impact of new software implementation as a factor affecting the company's growth, although they expressed optimism about BioTE's long-term prospects.
Additionally, the Board of Directors and CEO of BioTE showed confidence in the company's future by purchasing approximately 260,000 shares of its common stock. The company's leadership emphasized the potential for growth and the strategic initiatives in place, including the expansion of the BioTRx wellness platform. BioTE's revenue guidance for 2025 is set between $200 million and $280 million, with expected growth in procedure and dietary supplement revenues. Despite the challenges, BioTE continues to lead in the Bioidentical Hormone Replacement Therapy market, with plans to enhance its practitioner network and expand its product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.